↓ Skip to main content

Cochrane Database of Systematic Reviews

Cyclophosphamide for multiple sclerosis

Overview of attention for article published in Cochrane database of systematic reviews, January 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

blogs
1 blog
patent
1 patent
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
83 Mendeley
Title
Cyclophosphamide for multiple sclerosis
Published in
Cochrane database of systematic reviews, January 2007
DOI 10.1002/14651858.cd002819.pub2
Pubmed ID
Authors

Loredana La Mantia, Clara Milanese, Nerina Mascoli, Roberto D'Amico, Bianca Weinstock-Guttman

Abstract

Multiple sclerosis is a presumed cell-mediated autoimmune disease of the central nervous system. Cyclophosphamide (CFX) is a cytotoxic and immunosuppressive agent, used in systemic autoimmune diseases. Controversial results have been reported on its efficacy in MS. We conducted a systematic review of all relevant trials, evaluating the efficacy of CFX in patients with progressive MS.

Mendeley readers

The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 2%
Unknown 81 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 16%
Researcher 11 13%
Student > Bachelor 10 12%
Student > Ph. D. Student 7 8%
Student > Postgraduate 6 7%
Other 22 27%
Unknown 14 17%
Readers by discipline Count As %
Medicine and Dentistry 37 45%
Nursing and Health Professions 7 8%
Neuroscience 6 7%
Agricultural and Biological Sciences 5 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 8 10%
Unknown 17 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2020.
All research outputs
#1,707,436
of 16,810,341 outputs
Outputs from Cochrane database of systematic reviews
#4,251
of 11,596 outputs
Outputs of similar age
#26,952
of 235,908 outputs
Outputs of similar age from Cochrane database of systematic reviews
#107
of 242 outputs
Altmetric has tracked 16,810,341 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,596 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.4. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,908 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 242 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.